Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
This study is currently recruiting participants.
(see Contacts and Locations)
Verified May 2017 by National Cancer Institute (NCI)
Sponsor:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01822509
First received: April 1, 2013
Last updated: May 23, 2017
Last verified: May 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Study Completion Date: | No date given |
| Estimated Primary Completion Date: | December 31, 2018 (Final data collection date for primary outcome measure) |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):